Hennion & Walsh Asset Management Inc. lowered its stake in ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) by 45.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,938 shares of the biopharmaceutical company's stock after selling 30,852 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.05% of ChemoCentryx worth $915,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of CCXI. Bank of America Corp DE increased its holdings in shares of ChemoCentryx by 8.2% in the fourth quarter. Bank of America Corp DE now owns 76,895 shares of the biopharmaceutical company's stock valued at $2,799,000 after purchasing an additional 5,810 shares during the period. Dimensional Fund Advisors LP grew its holdings in ChemoCentryx by 1.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 147,382 shares of the biopharmaceutical company's stock worth $5,366,000 after acquiring an additional 2,718 shares during the period. HighTower Advisors LLC acquired a new position in ChemoCentryx during the fourth quarter worth $266,000. Invesco Ltd. grew its holdings in ChemoCentryx by 15.7% during the fourth quarter. Invesco Ltd. now owns 1,218,188 shares of the biopharmaceutical company's stock worth $44,355,000 after acquiring an additional 164,864 shares during the period. Finally, Barclays PLC grew its holdings in ChemoCentryx by 246.6% during the fourth quarter. Barclays PLC now owns 151,216 shares of the biopharmaceutical company's stock worth $5,506,000 after acquiring an additional 254,367 shares during the period. Institutional investors and hedge funds own 81.09% of the company's stock.
Get
ChemoCentryx alerts:
Insider Activity
In other news, Treasurer Markus J. Cappel sold 7,564 shares of the company's stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $50.22, for a total value of $379,864.08. Following the sale, the treasurer now directly owns 87,658 shares in the company, valued at $4,402,184.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Treasurer Markus J. Cappel sold 7,564 shares of the company's stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $50.22, for a total value of $379,864.08. Following the sale, the treasurer now directly owns 87,658 shares in the company, valued at $4,402,184.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James L. Tyree sold 10,000 shares of the stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $50.22, for a total value of $502,200.00. Following the transaction, the director now owns 9,138 shares in the company, valued at $458,910.36. The disclosure for this sale can be found here. Insiders have sold 213,760 shares of company stock worth $10,749,838 over the last three months. 8.30% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
A number of brokerages recently weighed in on CCXI. HC Wainwright lowered ChemoCentryx from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $101.00 to $52.00 in a report on Friday, August 5th. Canaccord Genuity Group lowered ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 price objective on the stock. in a report on Friday, August 5th. SVB Leerink lowered ChemoCentryx from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $64.00 to $52.00 in a report on Friday, August 5th. StockNews.com raised ChemoCentryx from a "sell" rating to a "hold" rating in a report on Wednesday, August 10th. Finally, Stifel Nicolaus lowered ChemoCentryx from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th. Six research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, ChemoCentryx presently has an average rating of "Hold" and a consensus price target of $65.25.
ChemoCentryx Price Performance
Shares of NASDAQ:CCXI opened at $51.66 on Friday. The company has a quick ratio of 4.47, a current ratio of 4.54 and a debt-to-equity ratio of 0.02. ChemoCentryx, Inc. has a 52-week low of $14.95 and a 52-week high of $51.85. The stock's fifty day simple moving average is $46.78 and its 200-day simple moving average is $31.13. The company has a market capitalization of $3.69 billion, a P/E ratio of -27.33 and a beta of 1.25.
About ChemoCentryx
(Get Rating)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Recommended Stories
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
